135 related articles for article (PubMed ID: 38661575)
21. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
22. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
23. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
24. The prostate cancer pseudo-epidemic.
Adami HO
Acta Oncol; 2010 Apr; 49(3):298-304. PubMed ID: 20397765
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
26. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
27. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
Hugosson J; Aus G; Becker C; Carlsson S; Eriksson H; Lilja H; Lodding P; Tibblin G
BJU Int; 2000 Jun; 85(9):1078-84. PubMed ID: 10848699
[TBL] [Abstract][Full Text] [Related]
28. Expected population impacts of discontinued prostate-specific antigen screening.
Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
[TBL] [Abstract][Full Text] [Related]
29. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
30. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
[TBL] [Abstract][Full Text] [Related]
31. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
32. Capture rate and representativity of The National Prostate Cancer Register of Sweden.
Tomic K; Berglund A; Robinson D; Hjälm-Eriksson M; Carlsson S; Lambe M; Stattin P
Acta Oncol; 2015 Feb; 54(2):158-63. PubMed ID: 25034349
[TBL] [Abstract][Full Text] [Related]
33. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
34. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
35. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
Jonsson H; Holmström B; Duffy SW; Stattin P
Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Brachlow J; Kälin M; Randazzo M; Förster B; John H
Praxis (Bern 1994); 2016 Aug; 105(16):971-7. PubMed ID: 27524169
[No Abstract] [Full Text] [Related]
38. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
39. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
40. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
